Can a wakefulness-promoting agent augment schizophrenia treatment?
Schizophrenia has plagued Mr. X for most of his adult life. He finally responds to a novel antipsychotic after many failed trials, but severe negative symptoms and medication-associated sedation are stalling his progress. In their efforts to reintegrate the patient, these doctors pose the question:
Author affiliations
Benjamin P. Yu, MD
Resident physician
Gerald A. Maguire, MD
Assistant dean for continuing medical education, Director of residency training,
Associate clinical professor
Department of psychiatry and human behavior
University of California-Irvine Medical Center
Disclosure
Dr. Yu reports that he serves on the speaker’s bureau of Cephalon Inc.
Dr. Maguire reports that he receives research/grant support from, serves as a consultant to, and is on the speaker’s bureau of Eli Lilly & Co.
